Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.
Neisseria meningitidis is a major cause of bacterial meningitis worldwide, especially in the African meningitis belt, and has a high associated mortality. The meningococcal serogroups A, W, and X have been responsible for epidemics and almost all cases of meningococcal meningitis in the meningitis b...
Main Authors: | Micoli, F, Romano, MR, Tontini, M, Cappelletti, E, Gavini, M, Proietti, D, Rondini, S, Swennen, E, Santini, L, Filippini, S, Balocchi, C, Adamo, R, Pluschke, G, Norheim, G, Pollard, A, Saul, A, Rappuoli, R, MacLennan, C, Berti, F, Costantino, P |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2013
|
Similar Items
-
Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine.
by: Snape, MD, et al.
Published: (2009) -
Strain selection for generation of O-antigen-based glycoconjugate vaccines against invasive nontyphoidal salmonella disease
by: Lanzilao, L, et al.
Published: (2015) -
Impact and Control of Sugar Size in Glycoconjugate Vaccines
by: Giuseppe Stefanetti, et al.
Published: (2022-09-01) -
Exploring the variables influencing the immune response of traditional and innovative glycoconjugate vaccines
by: Francesca Micoli, et al.
Published: (2023-05-01) -
Immunogenicity of a bivalent adjuvanted glycoconjugate vaccine against salmonella typhimurium and salmonella enteritidis.
by: Fiorino, F, et al.
Published: (2017)